MarginsXMarginsX
Home › Markets › Health Care › QCLS

Q/C Technologies Inc. (QCLS)

QCLS trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3210
+4.80% on the day
Market cap
$2.6M
Nano cap
Revenue · 2019
$1.6M
No prior year to compare
Net income · 2019
-$3.9M
-246.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/1321834/000149315220004650/0001493152-20-004650-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.

Profile

FieldValue
TickerQCLS on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year2014
SEC CIK0001321834
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2019

LineValue
Revenue$1.6M
Net income-$3.9M
Operating income-$3.5M
Net margin-246.6%
Operating margin-220.2%
Revenue growthNo prior-year revenue to compare
Cash$517K
Total assets$10.9M
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
0.4 months
$308K cash at June 30, 2026
Share count, 1 year
+363.7%
2025-08-18 to 2026-08-12 · +54583.5% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
$6K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-12
Cash and burn$308K cash; operating cash flow -$2.4M a quarter.Report 2026-06-30
Shares outstanding8,189,838 (2026-08-12); 176,615,658 a year earlier; 44,930,389 three years earlier. 1y figure adjusted for splits (1-for-100 overall); 3y figure adjusted for splits (1-for-3000 overall).Cover page 2026-08-12
Reverse splits, 3 years2; latest 1-for-100 on 2025-09-02Source 2025-09-02
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-11
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-11-13
AuditorGrassi & Co., CPAs, P.C., Glastonbury, Connecticut, United States; changed auditors 1 time in 24 months8-K 4.01 2026-03-13
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $6K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$6.6M-$1.8M$308KNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$1.2M-$3.3M$1.1MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2025
2025-12-31
Not filed-$5.9M-$3.2M$987KNo debt tagsNeeds four quarters10-K 2026-04-15
Q3 2025
2025-09-30
Not filed-$2.8M-$1.2M$6.9MNo debt tagsNeeds four quarters10-Q 2025-11-19
Q2 2025
2025-06-30
Not filed-$1.8M-$2.1M$208KNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$1.1M-$2.6M$73KNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2024
2024-12-31
Not filed-$2.1M-$2.1M$173KNo debt tagsNeeds four quarters10-K 2026-04-15
Q3 2024
2024-09-30
Not filed-$1.9M-$2.4M$1.2MNo debt tagsNeeds four quarters10-Q 2025-11-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-02-11
Latest annual report10-K/A2026-04-29
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-13
Latest proxyDEF 14A2025-10-20

Source: SEC EDGAR submissions feed, 606 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.8%
1 month-43.3%
3 months-89.2%
Year to date-92.2%
1 year-89.9%
From 52-week high-95.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
TRIBTrinity Biotech plc$5.38-11.89%$4.4M
CDIOCardio Diagnostics Holdings Inc.$1.79-7.26%$5.3M
BMRABiomerica Inc.$1.32-2.94%$6.1M
VNRXVolitionRX Limited$0.1998-13.13%$7.2M
VRAXVirax Biolabs Group Limited$0.4480-26.87%$603K
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
ICCCImmuCell Corporation$11.42+6.23%$103.8M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier